An efficient synthesis of carbamate analogues of the NRTI compound stavudine, has been achieved in five steps starting from commercially available thymidine. The synthesis involves conversion of thymidine into stavudine followed by condensation with carbaimidazole derivative obtained from various aromatic and heterocyclic amines in dimethylformamide solvent. The analogues thus obtained were further purified by crystallization to furnish analytically pure products. Examination of biological activity of these carbamate derivatives of stavudine showed that they inhibited HIV replication only at micro-molar concentrations.
Acquired immunodeficiency syndrome (AIDS) is the disease affecting major populations in recent years due to epidemic spread of human immunodeficiency virus (HIV) (Goldschmidt et al., 1997; Deeks 1998; Grob et al., 1992) . Three categories of antiretroviral agents in clinical use are nucleoside analogues, nucleoside reverse transcriptase inhibitors (NRTIs), such as zidovudine and stavudine (d4T), protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (Bell et al., 1995; Cantrell et al., 1996; Mao et al., 1998; . The 5′-triphosphates of 2′,3′-dideoxynucleoside analogues (ddNs) which are generated by the action of nucleoside and nucleotide kinases, are potent inhibitors of HIV reverse transcriptase (Furman et al., 1986; Hao et al., 1988) . The rate limiting step for the conversion of 3′-azido-3′-deoxythymidine (AZT) to its bioactive metabolite AZT-triphosphate seems to be the conversion of the monophosphate derivative to the diphosphate derivative, whereas the rate limiting step for the intracellular generation of the bioactive 2′,3′-dideoxy-2′,3′-didehydrothymidine (stavudine) metabolite stavudine-triphosphate was reported to be the conversion of the nucleoside to its monophosphate derivative (Balzarini et al., 1989; McGuigan et al., 1996a,b) . Anti-HIV ddN derivatives primarily rely on nucleoside and nucleotide kinases to convert them into the corresponding 5′-triphosphates as discussed before. However, such compounds were found to act as poor substrates for nucleoside kinases (Balzarini et al., 1987; Starnes et al., 1987; Johnson et al., 1988 Johnson et al., , 1989 Hao et al., 1990) . Consequently, development of prodrug strategies were sought which could bypass the initial nucleoside kinase activation. In an attempt to overcome the dependence of ddN analogues on intracellular nucleoside kinase activation, McGuigan and coworkers have prepared arylphosphate derivatives of zidovudine and stavudine (McGuigan et al., 1993 (McGuigan et al., , 1992 (McGuigan et al., , 1996a . We have prepared several aryl substituted phosphoramidate derivatives of stavudine and examined their antiviral activity against HIV-1 (Vig et al.; , Uckun et al., 2002 . In addition we also examined the antiviral activity profiles of non-nulceoside analogues such as PETT (phenylethylthiazolylthiourea) derivatives and found that these derivatives were useful as anti-HIV agents (Bell et al., 1995; Cantrell et al., 1996; Mao et al., 1998; . Based on the successful outcome of the above classes of compounds, we sought to combine these two structural motifs in the same molecule. To this end, we prepared carbamate derivatives of stavudine by installing a urea unit in their structural framework. Our hypothesis was that such structural features of the molecule would impart pro-drug characteristics along with easily hydrolysable groups to release stavudine and consequently improve the therapeutic profile of these analogues. The latter aspect was important as observed in our previous phosphoramidate prodrug studies , Uckun et al., 2002 . 
Introduction
Furthermore, carbamate analogues are generally labile and prone to hydrolyze in aqueous media and hence we anticipated these carbamates may easily release stavudine for further phosphoralation step. The purpose of the present study was to evaluate carbamate analogues of stavudine as a new class of NRTI and compare their activity with phosphoramidate analogues to understand the role played by invoking a carbon centre in the molecule.
Materials and methods
All chemicals were purchased from Aldrich (Milwaukee, Wisc., USA) and were used without further purification. Unless otherwise noted, each reaction vessel was secured with a rubber septum, and the reaction was performed under nitrogen atmosphere.
1 H and 13 C NMR were obtained on a Varian Mercury 300 instrument at ambient temperature in d 6 -DMSO. Chemical shifts are reported as d values in parts per million downfield from tetramethylsilane (δ ppm) as an internal standard or from the residual dimethylsulfoxide signal (δ ppm for 1 H NMR or δ ppm for 13 C NMR). Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad peak. FT-IR spectra were recorded on a Nicolet Protege 460 spectrometer. Mass spectra were performed on a Hewlett Packard MALDI-TOF spectrometer (Model G2025A LD-TOF). Melting points were determined using a Melt John′s apparatus and are uncorrected. HPLCs were performed using a Hewlett Packard 1100 series instrument consisting of an automatic sampler, an electronic degasser, a thermostatic control unit, and a diode array detector in conjunction with a Chemstation software assembly. The column used was an analytical RP-18 Lichrospher column, 5 µm (4×250 mm) and eluent was methanol. The flow rate was maintained at 1.0 ml/min and the detection wavelength was set at 275 nm. The column was maintained at room temperature throughout the analysis. Column chromatography was performed using silica gel obtained from the Baker Company. The solvents used for elution varied depending on the compound and included either one or a combination of the following: ethyl acetate, methanol, chloroform, hexane, methylene chloride, THF and ether.
Stock HTLVIIIB virus
The HIV-1 strain HTLVIIIB, which was propagated in CCRF-CEM cells, was used in in-vitro assays of the anti-HIV-1 activity of the synthesized thiourea derivatives. Cell-free supernatants of HTLVIIIB infected CCRF-CEM cells were harvested, dispensed into 1 ml aliquots, and frozen at -80°C. Periodic titration of the stock virus was performed by examining its cytopathic effects in MT-2 cells.
In vitro assays of anti-HIV-1 activity
Normal human peripheral blood mononuclear cells (PBMC) from HIV-negative donors were cultured 72 h in RPMI 1640 supplemented with 20% (v/v) heat inactivated fetal bovine serum (FBS), 3% interleukin-2, 2 mM L-glutamine, 25 mM HEPES, 2 g/l NaHCO 3 , 50 µg/ml gentamicin, and 4 µg/ml phytohemagglutinin prior to exposure to HIV-1 at a multiplicity of infection (MOI) of 0.1 during a 1 h absorption period at 37°C in a humidified 5% CO 2 atmosphere. Subsequently, cells were cultured in 96-well microtitre plates (100 µcells/ml) in the presence of various concentrations of d4T carbamate derivatives and aliquots of culture supernatants were removed from the wells on the seventh day after infection for p24 antigen assays, as described previously . The p24 enzyme immunoassay (EIA) was the unmodified kinetic assay commercially available from Coulter Corporation/Immunotech, Inc. (Westbrooke, Me., USA), which utilizes a murine mAb to HIV core protein coated onto microwell strips to which the antigen present in the test culture supernatant samples binds. Percentage viral inhibition was calculated by comparing the p24 values from untreated infected cells (that is, virus controls).
HPLC experimental conditions
For the assays, Lichrospher (RP) column was used. The eluent used for HPLC was water/methanol mixture and a gradient run comprising of the following regime was adopted: 0-10 min (50% of each solvent to 100% MeOH, at a rate of change of 5% a minute) and 10-15 min (50% of each solvent). The column was maintained at room temperature. The flow rate was maintained at 1 ml/min, the detection wavelength was adjusted to 265 nm. Samples of 10-20 µl were used for analysis.
Pepsin studies
Enzymatic pepsin solution was prepared using the published USP procedure for simulated gastric fluid (USP, 2000) . The prepared pepsin solution was treated with d4T carbamate derivatives as follows: 500 µl of the pepsin solution was transferred into a centrifuge tube and to this was added 100 µl of (2 mg/ml) the carbamate analogues predissolved in methanol. The contents were vortexed for 2-3 min and placed in a constant temperature incubator at 37°C for 4 h. The centrifuge tube was taken from the oven and allowed to attain room temperature and centrifuged at 7000 ×g for 10 min. The supernatant was transferred using a pipetman to HPLC vials and assayed for d4T formation using the conditions mentioned in the experimental section.
Pancreatin studies
Pancreatin solution was prepared using the published USP procedure for simulated intestinal fluid (USP, 2000) . The TK Venkatachalam et al. procedure followed for the assay was identical to those described in the case of pepsin studies as above.
Serum studies
The procedure used for human serum was as follows: 300 µl of serum was transferred into a centrifuge tube followed by 100 µl of respective carbamate solution in methanol and the contents were vortexed for 5 min and incubated at 37°C for 4 h. After this period, the tubes were taken from the incubator and allowed to attain room temperature. The tubes were centrifuged at 7000×g for 10 min and the supernatant was transferred carefully to a HPLC vial using a pipetman. The assay for d4T formation was monitored as described in the experimental section.
Mouse liver homogenate studies A single mouse was sacrificed for this purpose and the liver was separated and homogenized in PBS buffer and stored at 0°C in ice bath. The 1.6 g liver homogenate was suspended in 2 ml of buffer solution. For the experiment, 5-8 mg of the d4T carbamates were weighed and dissolved in 3 ml of MeOH. 1 ml of the test compound was transferred into a centrifuge tube and 200 µl of liver homogenate was added. The tube was placed in an incubator for 1.5 h at 37°C. After this period, the mixture was centrifuged at 7000×g for 10 min. The separated supernatant was drawn out from the suspension and transferred to a HPLC vial for analysis.
Stability studies of stavudine carbamates
Stability studies were conducted at three different temperatures. For this purpose, a known amount of material was placed in a glass vial with cap and was stored as follows: the first set of vials were stored in refrigerator (2-8°C), the second set were stored at a stability station maintained at 25°C, and the third set stored at 40°C at another stability station. The vials were left for 4 days before analysis. The vials were taken out and allowed to reach room temperature and the samples were dissolved in methanol. These solutions were assayed using HPLC. The percentage of recovery of the starting compound was estimated using the area under curve observed for each sample.
Results and Discussion
Synthesis of d4T carbamates was accomplished using the steps shown in Scheme 1. The procedure followed for the synthesis of stavudine was similar to that of Mansuri et al. and Horwitz et al. (Horwitz et al., 1966; Mansuri et al., 1989) . In brief, thymidine was treated with mesyl chloride in pyridine to furnish the mesylate A in 90% yield. Treatment of the mesylate with three equivalent of sodium hydroxide in water gave the oxetane derivative (B). The reaction of oxetane B with potassium tertiary butoxide in dimethylsulfoxide after workup gave d4T in 50% yield as a white to yellowish powder. In the subsequent step, stavudine was dissolved in acetonitrile and carbadimidazole was added with stirring to obtain the imidazole derivative of stavudine (C). In the final step, compound C was reacted with primary amines in dimethylformamide and the solution was heated to 100°C for 15 h to obtain carbamates 1-12 in 70-80% yield as white solids. Crystallization of these compounds in ethanol gave analytically pure stavudine carbamates as white powders. The structures of the final products were confirmed by NMR, IR and HPLC analysis.
Compounds 1-12, as well as the parent compound stavudine, were tested side by side for their ability to inhibit HIV-1 replication in peripheral blood mononuclear cells (PBMCs) using the method reported in the experimental section. The carbamate derivatives of stavudine were less active than stavudine in PBMCs. Notably, in PBMCs, the 50% inhibitory concentration (IC 50 ) values for all the compounds tested were far higher than the IC 50 value of stavudine ( Table 1) .
The poor activity of the carbamate analogues of stavudine prompted the hypothesis that these compounds may be resistant to hydrolysis yielding a much smaller amount of the active stavudine-triphosphate. Therefore, we next evaluated the susceptibility of the compounds to hydrolysis. We first tried to hydrolyze compound 6, which has a paraBr substitution, using pig liver esterase and failed to obtain detectable amounts of stavudine even after 48 h of incubation at room temperature. We next subjected compound 6 to alkaline hydrolysis using sodium hydroxide (1N). The rate of hydrolysis was monitored over time using an HPLC method. Figure 1 shows the percentage of stavudine produced with time at three different temperatures. The rate of hydrolysis of the carbamate analogue was very slow at room temperature and the first order rate constant obtained was 3.52×10 -5 min -1 . The rate constants observed for 37°C and 50°C were 7.67×10 -5 and 3.48×10 -4 min -1 respectively. These results demonstrate that the carbamate analogues of stavudine are difficult to hydrolyze to form stavudine even under chemical hydrolysis conditions. In contrast, stampidine, a phosphoramidate derivative of stavudine containing the same phenoxy moiety with a para-Br substitution, was hydrolyzed 600 times faster than compound 6 and exhibited potent anti-HIV activity .
The amounts of stavudine formed after exposure of stavudine carbamates to various enzymatic hydrolysis conditions are given in Table 2 . Exposure to pepsin, pancreatin, human serum and liver homogenates from mice yielded less than 10% stavudine. The inability for sodium hydroxide as well as hydrolyzing enzymes to hydrolyze these carbamates prompted the hypothesis that these ©2002 International Medical Press ° Scheme 1. General synthetic scheme for preparation of stavudine derivatives molecules may exist in a compact conformation resistant to hydrolysis. Such a compact conformation framework for these compounds may arise from hydrogen bonding. In the absence of other experimental evidence and alternative explanation for the stability of these stavudine carbamates, molecular modelling studies were performed to further explore this possibility.
The building of the initial model of compound 6, the molecular simulations, and the analysis of different conformations were performed in Cerius 2 Modeling Environment (Cerius 2 User guide. April 1997, Molecular Simulations Inc., San Diego, Calif., USA). After initial building of compound 6, the model was refined using molecular mechanics minimization with PCFF force field and followed by molecular dynamics simulation. It was observed that the molecular model of 6 could adopt two different conformations. The lowest energy conformation (-147.1 kcal/mol) corresponds to the closed conformation, when the nitrogen atom of compound 6 is close to two oxygen atoms. The distance between hydrogen and both oxygen atoms is about 2.1-2.2 Å and the angle N-H…O is 152.9°and 120.5°(C=O and -O-respectively). The second conformation of compound 6 corresponds to the extended conformation of the molecule and has a higher energy (-114.4 kcal/mol). The energy of closed and The building of the initial model of compound 6, the molecular simulations, and the analysis of different conformations were performed in Cerius 2 Modelling Environment (Cerius 2 User guide. April 1997, Molecular Simulations Inc., San Diego, Calif., USA). Figure 2 . Stereoview of compound 6 using molecular modelling extended conformations of compound 6 were calculated after the full energy minimization of the molecular models.
The conformation of a representative carbamate, 6 for this example, is given in Figure 2 . The conformation shown was found to be the lowest energy conformation as per our expectation and it is involved with a 5-, 6-and 7-member ring formation that perhaps helps in lowering the energy. We propose that there is strong electrostatic interaction between the free NH and the oxygen atoms of both the pentose ring and the carbonyl group of thymine ring. The bond distances are well within the range for hydrogen bonding. Further work is warranted to confirm this aspect and we are in the process of obtaining the x-ray crystal structures of these carbamates.
The results on stability test conducted for carbamates at various temperatures are given in Table 3 . The percentage of recovery for the compounds was estimated using HPLC assay. From these results we conclude that the compounds are very stable even at elevated temperatures demonstrating that decomposition of these compounds did not take place at least under the experimental conditions used in our studies. Figures 3 and 4 show the HPLC chromatograms for samples kept at 40°C both for phenyl substituted stavudine carbamates as well as heterocyclic substituted stavudine carbamates. There were no differences in their stability (Table 3) .
Conclusions
We synthesized carbamate analogues of stavudine and examined their anti-viral activity. These carbamate derivatives inhibited HIV replication only at micromolar concen- TK Venkatachalam et al. 6 ©2002 International Medical Press 3350, 3168, 3039, 2939 , 2891 , 2817 , 1685 , 1537 , 1466 , 1333 , 1257 , 1155 1 H NMR (d 6 -DMSO): 11.33 (s, 1H, NH), 7.39-7.33 (m, 2H, NH and H6), 7.29-7.19 (m, 4H, Ph), 6.80 (m, 1H, H-1′), 6.39 (d, 1H, J=6.0 Hz, H-3′), 5.97-5.95 (d, 1H, J=6.0 Hz, H-2′), 4.88(s, 1H, H-4′), 4.26-4.22(dd, 1H, J=3.0, 3.0 Hz, H-5′), 4.03-3.97(dd, 1H, J=6.0, 6.0 Hz, H-5′), 3.22-3.15 (m, 2H, CH 2 ), 2.84-2.79 (t, 2H, CH 2 ), 1.72 (bs, 3H, CH 3 
Compound 2
Mp. 189-190°C; UV (MeOH): 266 nm; IR (cm -1 ): 3361, 3172, 3032, 2929, 2814, 1686, 1533, 1466, 1408, 1333, 1286, 1257, 1159; 1 H NMR (d 6 -DMSO): 11.34 (bs, 1H, NH), 7H, Ph, NHCOO, 6.79 (m, 1H, H1′), 1H, J=6.0 Hz, 1H, J=6.0 Hz, 
Compound 3
Mp. 159-160°C; UV (MeOH): 268 nm; IR (cm -1 ): 3379, 3149, 3036, 2958, 2883, 2821, 1677, 1601, 1587, 1529, 1494, 1467, 1365, 1333, 1256, 1136; 1 H NMR (d 6 -DMSO): 11.34 (s, 1H, NH), 1H, NH), 1H, Ph), 1H, J=6.0 Hz, Ph), 2H, J=6.0 Hz, Ph, 
Compound 4
Mp. 185-186°C; UV (MeOH): 264 nm; IR (cm -1 ): 3361, 3172, 3041, 2947, 2891, 2812, 1686, 1587, 1533, 1493, 1466, 1408, 1338, 1256, 
Compound 5
Mp. 186-187°C; UV (MeOH): 267 nm; IR (cm-1): 3377, 3172, 3039, 2947, 2875, 2816, 1697, 1527, 1466, 1410, 1331, 1311, 1251; 1 H NMR (d 6 -DMSO): 11.33 (s, 1H, NH), 1H, NH), 1H, J=0.9 Hz, H-6), 7.09-7.06 ): 3371, 3170, 3041, 2949 , 2870 , 2814 , 1693 , 1527 , 1468 , 1286 , 1254 1H NMR (d 6 -DMSO): 11.33 (s, 1H, NH), 7.45-7.42 (d, 2H, J=6.0 Hz, Ph), 7.30-7.27 (t, 1H, NHCOO), 7.17 (s, 1H, H-6), 7.15-7.12 
Compound 7
Mp. 179-180°C; UV (MeOH): 266 nm; IR (cm -1 ): 3371, 3176, 3041, 2928 , 2814 , 1697 , 1531 , 1468 , 1410 , 1331 
